Apellis Pharmaceuticals Plunges 13.7% on Disappointing Q1 Earnings

Apellis Pharmaceuticals, Inc. (APLS) experienced a significant drop of 13.7% in pre-market trading on May 7, 2025.

Apellis Pharmaceuticals, Inc. reported its first quarter 2025 financial results, revealing an earnings per share (EPS) of ($0.74), which fell short of analysts' expectations by 40 cents. This disappointing performance is likely a key factor contributing to the stock's decline.

The company had previously announced that it would host a conference call on May 7, 2025, to discuss its first quarter 2025 financial results. This call was intended to provide investors with a detailed overview of the company's performance and future outlook. However, the actual results presented during the call did not meet market expectations, leading to a negative market reaction.

Additionally, Apellis Pharmaceuticals had announced its participation in two upcoming investor conferences in May 2025. These conferences were expected to provide further insights into the company's strategic direction and financial health. However, the disappointing Q1 results may overshadow these upcoming events, as investors focus on the immediate financial performance.